Pelvic Inflammatory Disease

Pelvic Inflammatory Disease
PID.ppt

Pelvic Inflammatory Disease
Rosella Castilla
Pelvic Inflammatory Disease.ppt

Reproductive System Disorders
Reproductive System Disorders.ppt

Female Infertility
Female Infertility.ppt

Perspectives in Global Fertility and Infertility
Catherine L. Haggerty, PhD, MPH
Perspectives in Global Fertility and Infertility.ppt

Sexually Transmitted Diseases
John D. Kriesel, MD
Sexually Transmitted Diseases.ppt

Sexually Transmitted Infections
Sexually Transmitted Infections.ppt

The Role of Cell Organelles in Chlamydia’s Life Cycle
The Role of Cell Organelles.ppt

Sexually Transmitted Diseases/Infections
Sexually Transmitted Diseases/Infections.ppt

Urogenital and Sexually Transmitted Diseases
Jacquelyn G. Black
Urogenital and Sexually Transmitted Diseases.ppt

Care of the Client Experiencing Reproductive Dysfunctions
T. Dennis RNC, MSN
Client Experiencing Reproductive Dysfunctions.ppt

Drug Therapy of Sexually Transmitted Diseases
Drug Therapy of Sexually Transmitted Diseases.ppt
177 free access published articles

1. Mycoplasma genitalium: an emerging cause of pelvic inflammatory disease.
2. Treatment of acute pelvic inflammatory disease.
3. Detection of pelvic inflammatory disease: development of an automated case-finding algorithm using administrative data.
4. The role of Chlamydia trachomatis polymorphic membrane proteins in inflammation and sequelae among women with pelvic inflammatory disease.
5. Nonhuman primate models used to study pelvic inflammatory disease caused by Chlamydia trachomatis.
6. A practical approach to the diagnosis of pelvic inflammatory disease.
7. Association between pelvic inflammatory disease and abortions.
8. Xanthogranulomatous salpingitis as a rare pathologic aspect of chronic active pelvic inflammatory disease.
9. Uterine cervical non-gonococcal and non-chlamydial bacterial flora and its antibiotic sensitivity in women with pelvic inflammatory disease: did it vary over 20 years?
10. Adverse adolescent reproductive health outcomes after pelvic inflammatory disease.
11. Pelvic inflammatory disease.
12. Has the effectiveness of a single chlamydia test in preventing pelvic inflammatory disease over 12 months been overestimated?
13. Management of first-episode pelvic inflammatory disease in primary care: results from a large UK primary care database.
14. Krukenberg tumour simulating uterine fibroids and pelvic inflammatory disease.
15. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial.
16. Specific strains of Escherichia coli are pathogenic for the endometrium of cattle and cause pelvic inflammatory disease in cattle and mice.
17. The demographic, sexual health and behavioural correlates of Mycoplasma genitalium infection among women with clinically suspected pelvic inflammatory disease.
18. Incidence of pelvic inflammatory disease in a large cohort of women tested for Chlamydia trachomatis: a historical follow-up study.
19. [Infectious pathology: vulvovaginitis, sexually transmitted diseases, pelvic inflammatory disease, tubo-ovarian abscesses].
20. Community-based trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial.
21. Clinical presentation of Mycoplasma genitalium Infection versus Neisseria gonorrhoeae infection among women with pelvic inflammatory disease.
22. Subsequent sexually transmitted infection after outpatient treatment of pelvic inflammatory disease.
23. Failure of cefoxitin and doxycycline to eradicate endometrial Mycoplasma genitalium and the consequence for clinical cure of pelvic inflammatory disease.
24. [Imaging in pelvic inflammatory disease].
25. Do short-term markers of treatment efficacy predict long-term sequelae of pelvic inflammatory disease?
26. Pelvic inflammatory disease.
27. Role of anaerobes in acute pelvic inflammatory disease.
28. Chronic pelvic inflammatory disease and melasma in women.
29. Mycoplasma genitalium among women with nongonococcal, nonchlamydial pelvic inflammatory disease.
30. A serological study of the role of Mycoplasma genitalium in pelvic inflammatory disease and ectopic pregnancy.
31. Antibiotic therapy for acute pelvic inflammatory disease: the 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines.
32. Treatment of pelvic inflammatory disease.
33. Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials.
34. Pelvic inflammatory disease.
35. The clinical diagnosis of pelvic inflammatory disease--reuse of electronic medical record data from 189 patients visiting a Swedish university hospital emergency department.
36. Risk factors associated with pelvic inflammatory disease.
37. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.
38. [Clinical observation on integrated traditional Chinese and Western medicine therapy in treating patients with pelvic inflammatory disease: a report of 28 cases].
39. The challenge of pelvic inflammatory disease.
40. [Severe pelvic inflammatory disease. Response to ertapenem].
41. Pelvic inflammatory disease during the post-partum year.
42. Microbiology profile in women with pelvic inflammatory disease in relation to IUD use.
43. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease.
44. Adnexal masses caused by pelvic inflammatory disease: MR appearance.
45. Significant reduction in inflammatory response in the macaque model of chlamydial pelvic inflammatory disease with azithromycin treatment.
46. Improvement in the clinical cure rate of outpatient management of pelvic inflammatory disease following a change in therapy.
47. Douching, pelvic inflammatory disease, and incident gonococcal and chlamydial genital infection in a cohort of high-risk women.
48. Condom use and the risk of recurrent pelvic inflammatory disease, chronic pelvic pain, or infertility following an episode of pelvic inflammatory disease.
49. Ness RB, Randall H, Richter HE, Peipert JF, Montagno A, Soper DE, Sweet RL, Nelson DB, Schubeck D, Hendrix SL, Bass DC, Kip KE; Pelvic Inflammatory Disease Evaluation and Clinical Health Study Investigators.
50. Chlamydophila abortus pelvic inflammatory disease.
51. Ciprofloxacin-tinidazole combination, fluconazole- azithromicin-secnidazole-kit and doxycycline- metronidazole combination therapy in syndromic management of pelvic inflammatory disease: a prospective randomized controlled trial.
52. Diagnosis of pelvic inflammatory disease: time for a rethink.
53. Investigating the microbial aetiology of pelvic inflammatory disease.
54. Associations between Mycoplasma genitalium, Chlamydia trachomatis and pelvic inflammatory disease.
55. Associations between Mycoplasma genitalium, Chlamydia trachomatis, and pelvic inflammatory disease.
56. Accuracy of five different diagnostic techniques in mild-to-moderate pelvic inflammatory disease.
57. Measurement of IgG antibodies to Chlamydia trachomatis by commercial enzyme immunoassays and immunofluorescence in sera from pregnant women and patients with infertility, pelvic inflammatory disease, ectopic pregnancy, and laboratory diagnosed Chlamydia psittaci/Chlamydia pneumoniae infection.
58. Spectrum of CT findings in acute pyogenic pelvic inflammatory disease.
59. Chlamydia trachomatis in subfertile women undergoing uterine instrumentation. How we can help in the avoidance of iatrogenic pelvic inflammatory disease?
60. Pelvic inflammatory disease associated with Enterobius vermicularis.
61. Case report: abdominal cocoon associated with tuberculous pelvic inflammatory disease.
62. An update on pelvic inflammatory disease.
63. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus.
64. Transvaginal power Doppler findings in laparoscopically proven acute pelvic inflammatory disease.
65. Pelvic inflammatory disease.
66. Assessment of risk for pelvic inflammatory disease in an urban sexual health population.
67. Outpatient antibiotics for pelvic inflammatory disease.
68. Concerns regarding the Centers for Disease Control's published guidelines for pelvic inflammatory disease.
69. Pelvic inflammatory disease epidemiology: what do we know and what do we need to know?
70. Epidemiology of ectopic pregnancy during a 28 year period and the role of pelvic inflammatory disease.
71. Risk factors for a complicated clinical course among women hospitalized with pelvic inflammatory disease.
72. Peripheral blood T cell proliferative response to chlamydial organisms in gonococcal and non-gonococcal urethritis and presumed pelvic inflammatory disease.
73. Transvaginal salpingosonography for assessing tubal patency in women previously treated for pelvic inflammatory disease and benign ovarian tumors.
74. Drug treatment of common STDs: Part II. Vaginal infections, pelvic inflammatory disease and genital warts.
75. Pelvic inflammatory disease in the postmenopausal woman.
76. Pathogenesis of Chlamydia induced pelvic inflammatory disease.
77. Antibody response to the chlamydial heat-shock protein 60 in an experimental model of chronic pelvic inflammatory disease in monkeys (Macaca nemestrina).
78. Infertility following pelvic inflammatory disease.
79. Evaluation of ofloxacin in the treatment of laparoscopically documented acute pelvic inflammatory disease (salpingitis).
80. Risk factors for laparoscopically confirmed pelvic inflammatory disease: findings from Mumbai (Bombay), India.
81. How well is pelvic inflammatory disease managed in general practice? A postal questionnaire survey.
82. Anaerobes in pelvic inflammatory disease: implications for the Centers for Disease Control and Prevention's guidelines for treatment of sexually transmitted diseases.
83. MR imaging in pelvic inflammatory disease: comparison with laparoscopy and US.
84. Clinical utility of CA125 levels in predicting laparoscopically confirmed salpingitis in patients with clinically diagnosed pelvic inflammatory disease.
85. Adolescent girls and pelvic inflammatory disease: experience and practices of emergency department pediatricians.
86. Humoral immune response to conserved epitopes of Chlamydia trachomatis and human 60-kDa heat-shock protein in women with pelvic inflammatory disease.
87. Hospitalizations for pelvic inflammatory disease in Canada, 1983/84-1993/94.
88. The influence of demographic change and cumulative risk of pelvic inflammatory disease on the incidence of ectopic pregnancy.
89. Recovery of cytomegalovirus and herpes simplex virus from upper and lower genital tract specimens obtained from women with pelvic inflammatory disease.
90. Prevalence and correlates of antibody to chlamydial heat shock protein in women attending sexually transmitted disease clinics and women with confirmed pelvic inflammatory disease.
91. Evidence of genetic susceptibility to Chlamydia trachomatis-induced pelvic inflammatory disease in the pig-tailed macaque.
92. Pelvic inflammatory disease isolates of Neisseria gonorrhoeae are distinguished by C1q-dependent virulence for newborn rats and by the sac-4 region.
93. Antibody to chlamydial hsp60 predicts an increased risk for chlamydial pelvic inflammatory disease.
94. Association of Ureaplasma urealyticum biovars with clinical outcome for neonates, obstetric patients, and gynecological patients with pelvic inflammatory disease.
95. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients.
96. Ampicillin/Sulbactam vs. Cefoxitin for the treatment of pelvic inflammatory disease.
97. Trospectomycin in acute pelvic inflammatory disease: a preliminary report.
98. Screening for chlamydia to prevent pelvic inflammatory disease.
99. Chlamydial pelvic inflammatory disease.
100. Pelvic inflammatory disease and risk of ovarian cancer.
101. Risk factors for Chlamydia trachomatis pelvic inflammatory disease among sex workers in Nairobi, Kenya.
102. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection.
103. Anaerobic and aerobic microflora of pouch of Douglas aspirate v/s high vaginal swab in cases of pelvic inflammatory disease.
104. Significance of genital mycoplasmas in pelvic inflammatory disease: innocent bystander!
105. Pelvic Inflammatory Disease (PID).
106. Transvaginal sonography in suspected pelvic inflammatory disease.
107. Pelvic inflammatory disease and the risk of epithelial ovarian cancer.
108. Pelvic inflammatory disease among patients in a public health practice: profile and outcomes.
109. Chlamydia trachomatis in pelvic inflammatory disease.
110. Susceptibilities of Chlamydia trachomatis isolates causing uncomplicated female genital tract infections and pelvic inflammatory disease.
111. Pelvic inflammatory disease and involuntary infertility: prospective pilot observations.
112. Epidemiology and clinical outcome of patients hospitalized with pelvic inflammatory disease complicated by tubo-ovarian abscess.
113. Endometrial cultures in acute pelvic inflammatory disease.
114. Doxycycline or ofloxacin for outpatient chlamydial pelvic inflammatory disease? A cost-benefit and cost-effectiveness analysis.
115. Chlamydia trachomatis-specific antibodies in patients with pelvic inflammatory disease: comparison with isolation in tissue culture or detection with polymerase chain reaction.
116. Susceptibility of Neisseria gonorrhoeae associated with pelvic inflammatory disease to cefoxitin, ceftriaxone, clindamycin, gentamicin, doxycycline, azithromycin, and other antimicrobial agents.
117. Pelvic inflammatory disease.
118. Immunopathogenesis of chlamydial pelvic inflammatory disease: the role of heat-shock proteins.
119. Diagnostic evaluation of pelvic inflammatory disease.
120. [A case of pelvic paragonimiasis combined with myoma uteri and pelvic inflammatory disease].
121. Influence of the estrous cycle on the development of upper genital tract pathology as a result of chlamydial infection in the guinea pig model of pelvic inflammatory disease.
122. Detection of serum antibodies to Chlamydia trachomatis in patients with chlamydial and nonchlamydial pelvic inflammatory disease by the IPAzyme Chlamydia and enzyme immunoassay.
123. Pathogenesis of pelvic inflammatory disease.
124. Pelvic inflammatory disease. Current approaches.
125. Inpatient treatment for uncomplicated and complicated acute pelvic inflammatory disease: ampicillin/sulbactam vs. Cefoxitin.
126. Current cigarette smoking and risk of acute pelvic inflammatory disease.
127. Treatment of acute pelvic inflammatory disease in the ambulatory setting: trial of cefoxitin and doxycycline versus ampicillin-sulbactam.
128. Pelvic inflammatory disease: guidelines for prevention and management.
129. Intrauterine devices and pelvic inflammatory disease--a reanalysis of the literature.
130. Conservative management of pelvic abscess in recurrent pelvic inflammatory disease.
131. Antigen specific serum antibody response to Chlamydia trachomatis in patients with acute pelvic inflammatory disease.
132. Pelvic inflammatory disease.
133. Pelvic inflammatory disease.
134. Incidence of pelvic inflammatory disease.
135. Bilateral meralgia paresthetica associated with pelvic inflammatory disease.
136. Pelvic inflammatory disease: a family practice perspective.
137. Concentrations of tumor-associated trypsin inhibitor and C-reactive protein in serum in acute pelvic inflammatory disease.
138. Vaginal douching as a possible risk factor for pelvic inflammatory disease.
139. Audit of the management of pelvic inflammatory disease in general practice.
140. Management of chronic pelvic inflammatory disease with shortwave diathermy. A case report.
141. A forgotten factor in pelvic inflammatory disease: infection in the male partner.
142. A forgotten factor in pelvic inflammatory disease: infection in the male partner.
143. Pelvic inflammatory disease.
144. Treating pelvic inflammatory disease with doxycycline and metronidazole or penicillin and metronidazole.
145. Comparison of clinical and epidemiological characteristics of pelvic inflammatory disease classified by endocervical cultures of Neisseria gonorrhoeae and Chlamydia trachomatis.
146. Trends in hospitalization for pelvic inflammatory disease in Canada, 1971-81.
147. Persistence of chlamydial antibodies after pelvic inflammatory disease.
148. Self-reported pelvic inflammatory disease in the US: a common occurrence.
149. Chlamydial pelvic infection in cats: a model for the study of human pelvic inflammatory disease.
150. Pelvic inflammatory disease in patients infected with Chlamydia trachomatis: in vitro cell mediated immune response to chlamydial antigens.
151. Gonococcal pelvic inflammatory disease, oral contraceptives, and cervical mucus.
152. Antibiotic susceptibilities and auxotypes of Neisseria gonorrhoeae strains from women with pelvic inflammatory disease or uncomplicated infections.
153. Pelvic inflammatory disease associated with Chlamydia trachomatis infection after therapeutic abortion. A prospective study.
154. Chronic hyperamylasemia and chronic pelvic inflammatory disease.
155. General and Family Practice-Epitomes of Progress: Culdocentesis to Diagnose Ectopic Pregnancy and Pelvic Inflammatory Disease (PID).
156. Morbidity associated with pelvic inflammatory disease.
157. Trends in pelvic inflammatory disease in England and Wales.
158. Cefotaxime treatment of pelvic inflammatory disease.
159. Beta-lactam susceptibility of Neisseria gonorrhoeae isolates from pelvic inflammatory disease.
160. Pelvic inflammatory disease and the intrauterine device.
161. Pelvic inflammatory disease and the intrauterine device: findings in a large cohort study.
162. Chlamydia trachomatis as a cause of acute perihepatitis associated with pelvic inflammatory disease.
163. Pelvic inflammatory disease and intrauterine contraception.
164. Effect of age on pelvic inflammatory disease in nulliparous women using a copper 7 intrauterine contraceptive device.
165. Antichlamydial antibodies in pelvic inflammatory disease.
166. Pathogenesis of pelvic inflammatory disease.
167. Pathogenesis of pelvic inflammatory disease.
168. Pelvic inflammatory disease.
169. In vitro activity of p-hydroxybenzyl penicillin (penicillin X) and five other penicillins against Neisseria gonorrhoeae: comparisons of strains from patients with uncomplicated infections and from women with pelvic inflammatory disease.
170. Acute pelvic inflammatory disease and clinical response to parenteral doxycycline.
171. Treatment of pelvic inflammatory disease in an urban emergency service.
172. Tropical gynaecology. Pelvic inflammatory disease.
173. Cortisone and Antibiotic Therapy in Pelvic Inflammatory Disease.
174. Office gynecology; a review of present day diagnosis and management of pelvic inflammatory disease, and the three most common causes of vaginal discharges.
175. Pelvic inflammatory disease.
176. The Treatment of Pelvic Inflammatory Disease On the Gynecological Service at Harlem Hospital.
177. RESULTS FOLLOWING OPERATIVE TREATMENT OF PELVIC INFLAMMATORY DISEASE IN THE STANFORD UNIVERSITY CLINIC.